Around 15–25% of breast cancers are noted to overexpress the human epithelial growth factor receptor 2 (HER-2) [1–3], patients with HER-2 overexpression were associated with a poor prognosis, more disease relapse, and distant metastasis [3–6]. This evidence concerns the gene ERBB2 and breast carcinoma.